Cros

Global Tangential Flow Filtration Market Report 2023: Advantages In Comparison To Standard Or Normal Flow Filtration Driving Adoption - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023

Numerous scientific disciplines, including protein chemistry, immunology, molecular DNA/RNA/oligonucleotides, biochemistry, and microbiology, have been using tangential flow filtration techniques.

Key Points: 
  • Numerous scientific disciplines, including protein chemistry, immunology, molecular DNA/RNA/oligonucleotides, biochemistry, and microbiology, have been using tangential flow filtration techniques.
  • Based on product, the tangential flow filtration market is categorized into single-use tangential flow filtration systems, reusable tangential flow filtration systems, membrane filters, and filtration accessories.
  • The single use TFF systems acquired a significant growth rate in the tangential flow filtration market in 2021.
  • On the basis of region, the tangential flow filtration market is analyzed across North America, Europe, Asia Pacific, and LAMEA.

Elligo Health Research® Names Dawn Sauro as New Chief Operating Officer

Retrieved on: 
Thursday, January 5, 2023

Elligo Health Research , the largest healthcare-enabling research organization, today announced that Dawn Sauro has been named as Elligo’s Chief Operating Officer (COO) to help further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions.

Key Points: 
  • Elligo Health Research , the largest healthcare-enabling research organization, today announced that Dawn Sauro has been named as Elligo’s Chief Operating Officer (COO) to help further the company’s growth, efficiency, and mission of optimizing the intersection of healthcare and research through direct access to patients, new technology, and custom research practice management solutions.
  • View the full release here: https://www.businesswire.com/news/home/20230105005290/en/
    Dawn Sauro is Elligo Health Research’s new Chief Operating Officer.
  • Prior to joining Elligo, Sauro was Chief Development Officer at Clinipace Clinical Research (now Caidya) where she grew the organization to be a trusted partner for sponsors across a variety of therapeutic areas.
  • Prior roles also included President, Development Innovations at Sarah Cannon and Senior Vice President and General Manager, Hematology/Oncology at inVentiv Health (now Syneos).

Global Capillary Electrophoresis Strategic Business Report 2022: Featuring Agilent Technologies, Bio-Rad Laboratories, Danaher and Helena Laboratories Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023

The "Capillary Electrophoresis: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Capillary Electrophoresis: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • Academic Institutes & CROs, one of the segments analyzed in the report, is projected to record a 5.7% CAGR and reach US$614.7 Million by the end of the analysis period.
  • In the global Other End-Use segment, USA, Canada, Japan, China and Europe will drive the 4.3% CAGR estimated for this segment.
  • Latin America will expand at a 4.8% CAGR through the analysis period.

Global Cell Lysis & Disruption Market Analysis Report to 2029 - Increasing Acceptance of Advanced Lysis & Disruption Techniques Throughout Downstream Processing Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 28, 2022

Increasing acceptance of advanced lysis & disruption techniques throughout downstream processing for the production of biologics is a key driver for the growth of the global cell lysis & disruption market.

Key Points: 
  • Increasing acceptance of advanced lysis & disruption techniques throughout downstream processing for the production of biologics is a key driver for the growth of the global cell lysis & disruption market.
  • However, high cost of process implementation and lack of skilled professionals are expected to restrain the global market growth.
  • This is attributed to the selective product release application coupled with controlled lysis, thereby providing biological uniqueness to the process.
  • Based on application, the market is categorized into cell organelle isolation, downstream processing, protein isolation, and nucleic acid isolation.

$6.87 Billion Worldwide In-vivo CRO Industry to 2027: Players Include Charles River Laboratories International, Evotec, ICON and Iris Pharma - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 27, 2022

The "In-vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vivo CRO market size reached US$ 4.2 Billion in 2021.
  • Looking forward, the publisher expects the market to reach US$ 6.87 Billion by 2027, exhibiting a CAGR of 8.55% during 2021-2027.
  • Moreover, the extensive utilization of in-vivo CRO to perform toxicology and pharmacokinetic studies during preclinical activities is impelling the market growth.

Global Life Sciences BPO Market Analysis Report 2022: A $827.5 Billion Market by 2030 - Focus on Medical Devices Outsourcing, Pharmaceutical Outsourcing - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 22, 2022

The "Global Life Sciences BPO Market Size, Share & Trends Analysis Report by Service (Medical Devices Outsourcing, Pharmaceutical Outsourcing), by Region (North America, APAC), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Life Sciences BPO Market Size, Share & Trends Analysis Report by Service (Medical Devices Outsourcing, Pharmaceutical Outsourcing), by Region (North America, APAC), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global life sciences BPO market size is expected to reach USD 827.5 billion by 2030, registering a CAGR of 9.2% years.
  • The pharmaceutical and biotech industries invest heavily in the R&D sector to continuously introduce new molecules, devices, and treatments.
  • Altogether, these trends are expected to boost the life sciences outsourcing market over the forecast period.

AI-Based Clinical Trial Solutions for Patient Matching Market Report 2022: Growing Government Activities to Encourage the Use of Artificial Intelligence (AI) Drives Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022

The "AI-based Clinical Trial Solutions for Patient Matching Market by Therapeutic Application, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "AI-based Clinical Trial Solutions for Patient Matching Market by Therapeutic Application, by End-user, and by Region - Global Forecast to 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The AI-based clinical trial solutions market size is estimated to be USD 235.21 million in 2022 and is expected to witness a CAGR of 27.21% during the forecast period 2023-2033.
  • Growing government activities to encourage the use of artificial intelligence (AI) technologies in the healthcare industry is expected to drive the market growth.
  • Government entities in industrialized countries such as U.S. and Europe are funding the development of AI-based clinical trial study solutions even while establishing a strict regulatory framework.

Biologics Contract Development Global Market Report 2022: Expanding Adoption of Cutting-Edge Technologies for Biological Production Drives 10% Annual Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022

The "Biologics Contract Development Market by Product Service, by Indication, by Source, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biologics Contract Development Market by Product Service, by Indication, by Source, and by Region - Global Forecast to 2022-2033" report has been added to ResearchAndMarkets.com's offering.
  • The biologics contract development market size is estimated to be USD 5,672.1 million in 2022 and is expected to witness a CAGR of 10.71% during the forecast period 2023-2033.
  • However, lack of knowledge regarding the usage of products and high price of production is expected to hinder the growth.
  • Increase in the incidence of disorders such neurological disorders, gynaecological disorders, cancer, ophthalmic disorders, and cardiovascular problems is projected to spur the market.

Nippon Express (Deutschland) Participates in BIO-Europe, Showcasing Its Pharmaceutical Logistics Business in Germany

Retrieved on: 
Thursday, January 5, 2023

TOKYO, Jan. 5, 2023 /PRNewswire/ -- Nippon Express (Deutschland) GmbH (hereinafter "NX Germany"), a group company of NIPPON EXPRESS HOLDINGS, INC., took part in BIO-Europe for the first time ever last year while showcasing its pharmaceutical logistics business in Germany.

Key Points: 
  • TOKYO, Jan. 5, 2023 /PRNewswire/ -- Nippon Express (Deutschland) GmbH (hereinafter "NX Germany"), a group company of NIPPON EXPRESS HOLDINGS, INC., took part in BIO-Europe for the first time ever last year while showcasing its pharmaceutical logistics business in Germany.
  • BIO-Europe, one of Europe's largest business-matching events in the biotech field (drug discovery, drug discovery support, regenerative medicine, etc.
  • ), was held in Leipzig, Germany, for three days from Monday, October 24, to Wednesday, October 26, 2022.
  • The Nippon Express Group will continue expanding its pharmaceutical logistics services in Europe and stepping up its global efforts in the pharmaceutical industry, positioned as a priority industry in the Group's Business Plan.

Ganymede Bio, the Cloud Provider Purpose-Built for the Life Sciences and Manufacturing Industries, Raises $12.75 Million in Series A Funding

Retrieved on: 
Tuesday, December 20, 2022

Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, today announced a $12.75 million Series A funding round, led by Caffeinated Capital.

Key Points: 
  • Ganymede Bio, the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries, today announced a $12.75 million Series A funding round, led by Caffeinated Capital.
  • This follows a $2.9 million seed round completed earlier this year, bringing the total to over $15.6 million.
  • “Scientific software, especially for biotechs, is 10 to 20 years behind other industries,” said Nathan Clark, co-founder of Ganymede Bio.
  • Ganymede is the cloud infrastructure provider purpose-built for the life sciences and manufacturing industries.